Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
REGRANEX vs ACTISITE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Recombinant human platelet-derived growth factor (rh PDGF-BB) that promotes chemotaxis and proliferation of fibroblasts, smooth muscle cells, and other cells involved in wound healing, and stimulates granulation tissue formation.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.
Treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have adequate blood supply.,Off-label: pressure ulcers, venous stasis ulcers, other chronic wounds.
Treatment of periodontal disease (adjunct to scaling and root planing),Topical treatment of infected wounds and skin ulcers
Apply topically once daily, a thin layer to the full area of the ulcer, using a measured amount of gel based on ulcer length and width in centimeters: (length × width × 0.5) grams.
Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.
Terminal half-life ~30-60 minutes after topical application; prolonged in renal impairment (up to 2-3 hours). Clinical context: Short systemic exposure limits off-target effects.
Not applicable due to local degradation; systemic half-life is negligible as tetracycline hydrochloride is not absorbed.
Metabolized locally; no systemic metabolism expected due to topical administration and minimal absorption. If absorbed, degraded by proteolytic enzymes at the wound site.
Not significantly metabolized; primarily excreted unchanged in urine and feces.
Primarily renal; minimal biliary/fecal. Becaplermin is cleared renally (>90% as metabolites) with <2% excreted unchanged. Fecal elimination accounts for <10%.
Primarily eliminated by phagocytic degradation at the application site; minimal systemic absorption, negligible renal or biliary excretion.
~25% bound to plasma proteins (primarily albumin).
Not applicable (no systemic absorption); if systemically present, tetracycline is 50-60% bound to plasma proteins.
Vd ~12 L (~0.17 L/kg assuming 70 kg), indicating limited extravascular distribution due to molecular size.
Not applicable due to lack of systemic absorption; if systemic, tetracycline Vd is 1.3-1.6 L/kg.
Topical: Negligible systemic bioavailability (<1% of applied dose absorbed; increased with large wounds or impaired skin barrier).
Negligible systemic bioavailability (<0.1%) when applied topically; not administered orally or intravenously for periodontal use.
No dose adjustment required for renal impairment.
Not systemically absorbed; no renal adjustment required.
No dose adjustment required for hepatic impairment.
Not systemically absorbed; no hepatic adjustment required.
Safety and efficacy in pediatric patients have not been established; use not recommended.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment recommended; use with caution due to potential comorbidities and polypharmacy.
No specific dose adjustment; use standard adult dosing with caution for age-related comorbidities.
Increased risk of mortality secondary to malignancy in patients treated with 3 or more tubes of REGRANEX (becaplermin) Gel. A postmarketing study showed increased mortality from cancer in patients who used three or more tubes of REGRANEX compared to control patients. REGRANEX should only be used when the benefits can be expected to outweigh the risks. REGRANEX is not recommended in patients with known malignancy.
None
Application to wounds with active malignancy may promote tumor growth. Application to wounds with infection or necrotic tissue should be discontinued until infection is controlled or necrotic tissue debrided. Potential for immunogenicity.
Photosensitivity,Superinfection with resistant organisms,Use in renal impairment may require dose adjustment,Not recommended in children under 8 years due to permanent tooth discoloration
Known hypersensitivity to becaplermin or any product component. Application to wounds with known neoplasms or active malignancy. Use on wounds closed by primary intention.
Hypersensitivity to tetracyclines,Severe renal impairment
No known food interactions. Regranex is applied topically and has minimal systemic absorption.
No direct food interactions. Avoid eating on the treated side to prevent dislodgement of the fiber. Maintain soft diet to minimize trauma. Avoid alcohol-based mouthwashes.
No adequate and well-controlled studies in pregnant women. Animal studies at doses 25-100 times human exposure show no fetal harm. Risk cannot be ruled out; use only if potential benefit justifies potential risk.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, tetracycline hydrochloride (active component) caused fetal toxicity (skeletal malformations, reduced fetal weight) at doses 1-2 times the human dose. First trimester: potential for teratogenicity (neural tube defects, cardiovascular anomalies). Second and third trimesters: risk of permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus; also potential for inhibition of fetal bone growth and maternal hepatotoxicity. Use only if potential benefit outweighs risk.
It is not known whether becaplermin is excreted in human milk. M/P ratio unknown. Use caution; consider developmental and health benefits of breastfeeding along with mother's clinical need for REGRANEX.
Tetracycline is excreted in human milk (M/P ratio approximately 0.6-1.5). Due to potential for serious adverse reactions (tooth discoloration, bone growth inhibition, photosensitivity) in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Avoid prolonged use during breastfeeding.
No pharmacokinetic data in pregnancy. Dosage adjustments are not recommended based on current knowledge; use same dosing as non-pregnant adults.
No specific dose adjustments for ACTISITE (tetracycline periodontal fiber). Systemic absorption minimal (peak serum concentrations <0.1 mcg/m L). Pregnancy may alter pharmacokinetics of tetracycline (increased volume of distribution, decreased protein binding), but due to local administration, systemic effects are negligible. No dosage adjustment required for the fiber formulation; however, avoid systemic tetracycline use during pregnancy when possible.
Regranex (becaplermin) is a recombinant platelet-derived growth factor (PDGF) gel indicated for diabetic neuropathic ulcers extending into subcutaneous tissue or deeper. Ensure ulcer is free of infection, necrotic tissue, and has adequate blood supply before initiating therapy. Apply a thin layer once daily, and recalibrate gel amount based on ulcer dimensions (length x width x 0.5 for cm to grams). Do not use on wounds with exposed bone, tendon, or joint. Monitor for increased risk of malignancy; contraindicated in patients with active malignancies. The gel is for single-patient use only; discard tube 30 days after opening.
ACTISITE (tetracycline hydrochloride) periodontal fiber is a controlled-release local antibiotic for adjunctive treatment of chronic periodontitis. Insert fiber into periodontal pocket to deliver drug over 10 days. Ensure pocket depth is ≥5mm. Do not use with metallic or synthetic fibers. Fiber must be secured with cyanoacrylate adhesive. Monitor for foreign body sensation, pain, or infection. Removal at 10 days is mandatory to avoid excessive tissue reaction. Not for acute abscesses.
Wash hands before and after applying Regranex.,Clean the ulcer gently with saline or water before each application.,Apply a thin layer of gel (about 1/16 inch) to the entire ulcer area once daily.,Cover the ulcer with a saline-moistened gauze dressing after applying gel.,Do not use more than the prescribed amount or frequency.,Store Regranex in the refrigerator; do not freeze.,Discard any unused gel in the tube 30 days after first opening.,Report any signs of infection (increased pain, redness, swelling, foul odor) or new skin changes around the wound.,You may need to have your wound measured weekly to adjust the gel amount.,Avoid applying other creams, ointments, or lotions to the same area.
Do not brush or floss the treated area while the fiber is in place.,Avoid chewing hard or sticky foods on the treated side.,You may feel a mild foreign body sensation; report severe pain or swelling.,The fiber must be removed after 10 days; do not leave it longer.,Complete the full course of prescribed oral hygiene and antibiotics if given.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about REGRANEX vs ACTISITE, answered by our medical review team.
REGRANEX is a Topical Growth Factor (Platelet-Derived) that works by Recombinant human platelet-derived growth factor (rh PDGF-BB) that promotes chemotaxis and proliferation of fibroblasts, smooth muscle cells, and other cells involved in wound healing, and stimulates granulation tissue formation.. ACTISITE is a Tetracycline Antibiotic that works by Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between REGRANEX and ACTISITE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of REGRANEX is: Apply topically once daily, a thin layer to the full area of the ulcer, using a measured amount of gel based on ulcer length and width in centimeters: (length × width × 0.5) grams.. The standard adult dose of ACTISITE is: Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between REGRANEX and ACTISITE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. REGRANEX is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal studies at doses 25-100 times human exposure show no fetal harm. Risk cannot be ruled out; use only if potential b. ACTISITE is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, tetracycline hydrochloride (active component) caused fetal toxicity (skeletal malformations, red. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.